<?xml version="1.0" encoding="UTF-8"?>
<document><pages><item><additional-info><aditional1>  &#13;
                    &lt;h4&gt;REMISSION (PRIMARY ENDPOINT)&lt;/h4&gt; &#13;
                    &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-1-1.jpg"&gt;&lt;/div&gt;&#13;
                    &lt;p class="bulet"&gt;&lt;strong&gt;Primary endpoint:&lt;/strong&gt; remission&lt;sup&gt;a&lt;/sup&gt; rates at week 8 for XELJANZ 10 mg BID vs placebo by prior TNFi exposure at baseline:&lt;sup&gt;1,2&lt;/sup&gt; &lt;/p&gt;&#13;
                    &lt;ul&gt;&#13;
                        &lt;li&gt;Total population:&lt;sup&gt;b&lt;/sup&gt; 18% vs 6%, respectively&lt;/li&gt;&#13;
                        &lt;li&gt;TNFi-naïve patients: (OCTAVE Induction 1) 25% vs 16%, respectively; (OCTAVE Induction 2) 22% vs 9%, respectively&lt;/li&gt;&#13;
                        &lt;li&gt;Patients with prior TNFi failure: (OCTAVE Induction 1) 11% vs 2%, respectively; (OCTAVE Induction 2) 12% vs 0%, respectively&lt;/li&gt;&#13;
                    &lt;/ul&gt;&#13;
                    &lt;p class="bulet"&gt;Clinical response was defined as a decrease from induction-trial baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;                          &#13;
                    &#13;
                    &lt;div class="modal-images"&gt;&#13;
                        &lt;div class="left"&gt;&#13;
                            &lt;h4&gt;STOOL FREQUENCY&lt;/h4&gt;&#13;
                            &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-1-2.png"&gt;&lt;/div&gt;&#13;
                        &lt;/div&gt;&#13;
                        &lt;div class="right"&gt;&#13;
                            &lt;h4 style="text-align: left;text-transform: uppercase;"&gt;rectal bleeding&lt;/h4&gt;&#13;
                            &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-1-3.png"&gt;&lt;/div&gt;&#13;
                        &lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                    &lt;p class="bulet"&gt;XELJANZ demonstrated rapid onset, significantly reducing stool frequency&lt;sup&gt;c&lt;/sup&gt; and rectal bleeding&lt;sup&gt;d&lt;/sup&gt; in as early as 3 days in a post hoc analysis&lt;sup&gt;e&lt;/sup&gt; of two phase 3 induction studies&lt;sup&gt;3&lt;/sup&gt;&lt;/p&gt;&#13;
                    &lt;p class="bulet"&gt;Post hoc analysis&lt;sup&gt;e&lt;/sup&gt; in OCTAVE Induction 1 and 2: daily bowel movement data were collected from patients to calculate the Mayo stool frequency and rectal bleeding subscores. For post hoc analyses, baseline values for Mayo subscores were derived using average data from 3 of the 5 days before first dose. Change from baseline was determined based on diary data for each day during the first 15 days of therapy&lt;sup&gt;3&lt;/sup&gt;&lt;/p&gt;&#13;
                    &#13;
                    &lt;div class="small"&gt;&#13;
                        &lt;p&gt;&lt;sup&gt;a&lt;/sup&gt;Remission (primary endpoint) was defined as a total Mayo score ≤2 with no individual subscore &gt;1 and rectal bleeding subscore of 0.&lt;sup&gt;2&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;b&lt;/sup&gt;Includes all patients, TNFi naïve and TNFi exposed.&lt;sup&gt;2&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;c&lt;/sup&gt;Proportion of patients with a reduction from baseline Mayo stool frequency subscore of ≥1 point excludes patients with a baseline Mayo stool frequency subscore of 0.&lt;sup&gt;3&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;d&lt;/sup&gt;Proportion of patients with a reduction from baseline Mayo rectal bleeding subscore of ≥1 point excludes patients with a baseline Mayo rectal bleeding subscore of 0.&lt;sup&gt;3&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;e&lt;/sup&gt;Limitations of post hoc analysis: these analyses were post hoc, and data were based on daily telephone diary entries. Onset of XELJANZ efficacy in the wider population of patients with UC may differ. XELJANZ plasma concentration may not be at steady state until 24 to 48 hours after initial dosing; therefore, these analyses should be interpreted with caution.&lt;sup&gt;3,4&lt;/sup&gt;&#13;
                        &lt;br/&gt;BID, twice daily; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis.&lt;/p&gt;&#13;
                    &lt;/div&gt;</aditional1><additional2>&#13;
                &lt;div class="modal-images"&gt;&#13;
                    &lt;div class="left"&gt;&#13;
                        &#13;
                        &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-2-1.png"&gt;&lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                    &lt;div class="right"&gt;&#13;
                        &#13;
                        &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-2-2.jpg"&gt;&lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                &lt;/div&gt;&#13;
                &lt;p class="bulet"&gt;&lt;strong&gt;Primary endpoint:&lt;/strong&gt; XELJANZ 5 mg BID demonstrated durable remission&lt;sup&gt;a&lt;/sup&gt; vs placebo at week 52, regardless of prior TNFi status at baseline&lt;sup&gt;1,2&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;ul&gt;&#13;
                    &lt;li&gt;Total population:&lt;sup&gt;c&lt;/sup&gt; 34% vs 11%, respectively; P&lt;0.001&lt;sup&gt;1,2&lt;/sup&gt;&lt;/li&gt;    &#13;
                    &lt;li&gt;Patients without prior TNFi failure: 42% vs 11%, respectively; P&lt;0.0001&lt;sup&gt;2&lt;/sup&gt;&lt;/li&gt;&#13;
                    &lt;li&gt;Patients with prior TNFi failure: 24% vs 11%, respectively; P&lt;0.05&lt;sup&gt;2&lt;/sup&gt;&lt;/li&gt;&#13;
                &lt;/ul&gt;&#13;
                &lt;p class="bulet"&gt;&lt;strong&gt;Key secondary endpoint:&lt;/strong&gt; XELJANZ 5 mg BID delivered sustained steroid-free remission&lt;sup&gt;b&lt;/sup&gt; vs placebo in OCTAVE Sustain through week 52, regardless of prior TNFi status at baseline&lt;sup&gt;1,2&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;ul&gt;&#13;
                    &lt;li&gt;Total population:&lt;sup&gt;c&lt;/sup&gt; 35% vs 5%, respectively; P&lt;0.001&lt;sup&gt;1,2&lt;/sup&gt;&lt;/li&gt;    &#13;
                    &lt;li&gt;Patients without prior TNFi failure: 40% vs 5%, respectively; P&lt;0.01&lt;sup&gt;2&lt;/sup&gt;&lt;/li&gt;&#13;
                    &lt;li&gt;Patients with prior TNFi failure: 22% vs 5%, respectively&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#13;
                &lt;/ul&gt;&#13;
                &lt;p class="bulet"&gt;In a 52-week maintenance study (OCTAVE Sustain), patients who had completed the induction studies and achieved clinical response were &lt;br/&gt; re-randomised to XELJANZ 10 mg BID, XELJANZ 5 mg BID, or placebo (1:1:1 ratio). For patients with loss of response during maintenance treatment with 5 mg BID, a dosage of 10 mg BID may be considered and limited to the shortest duration.&lt;sup&gt;1&lt;/sup&gt; The primary endpoint was remission. Sustained corticosteroid-free remission among patients who were in remission at maintenance-trial entry was a key secondary endpoint. Patients were permitted to use stable doses of oral aminosalicylates, but initiation of corticosteroid tapering was required upon entrance to this study for patients who were receiving corticosteroids at baseline. Concomitant immunosuppressants (immunomodulators or biological therapies) were not permitted&lt;sup&gt;1-3&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;div class="small"&gt;&#13;
                    &lt;p&gt;&lt;strong&gt;Maintenance treatment with XELJANZ 10 mg BID should be limited to patients who are not at increased risk for VTE, who experience a decrease in response on XELJANZ 5 mg BID, or who fail to respond to alternative treatment options (eg, TNFi therapy). XELJANZ 10 mg BID for maintenance treatment should be used for the shortest duration possible. The lowest effective dose needed to maintain response should be used.&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&#13;
                    &lt;br/&gt;&lt;sup&gt;a&lt;/sup&gt;Remission (primary endpoint) was defined as a total Mayo score ≤2 with no individual subscore &gt;1 and rectal bleeding subscore of 0.&lt;sup&gt;4&lt;/sup&gt;&#13;
                    &lt;br/&gt;&lt;sup&gt;b&lt;/sup&gt;Sustained steroid-free remission was defined as being in remission and on no corticosteroids for at least 4 weeks prior to the visit at both week 24 and week 52 among those in remission at maintenance baseline.&lt;sup&gt;1,4&lt;/sup&gt;&#13;
                    &lt;br/&gt;&lt;sup&gt;c&lt;/sup&gt;Includes all patients, without and with prior TNFi failure.&lt;sup&gt;2&lt;/sup&gt;&#13;
                    &lt;br/&gt;BID, twice daily; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis; VTE, venous thromboembolism.&lt;/p&gt;&#13;
            &lt;/div&gt; </additional2><additional3>&#13;
                &lt;p&gt;&lt;strong&gt;The safety profile for XELJANZ was studied across 3 large placebo-controlled phase 3 clinical trials (2 induction and 1 maintenance) that included 1139 patients with moderate to severe UC, and an open-label safety and tolerability study&lt;sup&gt;1,2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#13;
                &lt;br/&gt;&#13;
                &lt;div class="etention"&gt;&#13;
                    &lt;div class="middle"&gt;&lt;p&gt;XELJANZ offers nearly 8 years of long-term safety data in UC (median exposure: 1.7 years)&lt;sup&gt;3,a&lt;/sup&gt;&lt;/p&gt;&lt;/div&gt;&#13;
                &lt;/div&gt;&#13;
                &lt;br/&gt;&lt;br/&gt;&#13;
                &lt;p&gt;&lt;strong style="font-size: 1.1em;"&gt;Adverse reactions&lt;/strong&gt;&lt;/p&gt;&#13;
                &lt;p class="bulet"&gt;In the induction and maintenance studies, the most common types of serious adverse reactions were gastrointestinal disorders and infections, and the most common serious adverse reaction was worsening of UC&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;br/&gt;&#13;
                &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-3-1.jpg"&gt;&lt;/div&gt;&#13;
                &lt;br/&gt;&#13;
                &lt;p&gt;&lt;strong style="font-size: 1.2em;"&gt;Use in patients over 65 years of age&lt;/strong&gt;&lt;/p&gt;&#13;
                &lt;p class="bulet"&gt;Considering the increased risk of serious infections, MI, and malignancies with XELJANZ in patients over 65 years of age, XELJANZ should only be used in these patients if no suitable treatment alternatives are available&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;br/&gt;&#13;
                &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-3-2.jpg"&gt;&lt;/div&gt;&#13;
                &#13;
                &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-3-3.jpg"&gt;&lt;/div&gt;&#13;
                &lt;br/&gt;&#13;
                &lt;p&gt;&lt;strong style="font-size: 1.1em;"&gt;Hepatic impairment&lt;/strong&gt;&lt;br/&gt;&lt;/p&gt;&#13;
                    &lt;p class="bulet"&gt;Use of XELJANZ in patients with severe hepatic impairment is not recommended&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                    &lt;p&gt;&lt;strong style="font-size: 1.1em;"&gt;Use in pregnancy&lt;/strong&gt;&lt;br/&gt;&lt;/p&gt;&#13;
                    &lt;p class="bulet"&gt;There are no adequate and well-controlled studies on the use of XELJANZ in pregnant women. As a precautionary measure, the use of XELJANZ in pregnant women is contraindicated&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;p class="bulet"&gt;Women of childbearing potential should be advised to use effective contraception during treatment with XELJANZ and for at least 4 weeks after the last dose&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                    &lt;p&gt;&lt;strong style="font-size: 1.1em;"&gt;VTE&lt;/strong&gt;&lt;br/&gt;&lt;/p&gt;    &#13;
                    &lt;p class="bulet"&gt;Serious VTE events, including PE (some of which were fatal) and DVT, have been observed in patients taking XELJANZ&lt;sup&gt;1&lt;/sup&gt; &lt;/p&gt;&#13;
                    &lt;p class="bulet"&gt;A dose-dependent increased risk for VTE was observed in a large, ongoing post-marketing safety study of patients with RA who were aged 50 and older with at least one CV risk factor and treated with XELJANZ 10 mg BID vs XELJANZ 5 mg BID or TNFis. The majority of these events were serious and some resulted in death&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                    &lt;br/&gt;&#13;
                &lt;div class="etention"&gt;&#13;
                    &lt;div class="middle"&gt;&lt;p&gt;XELJANZ 10 mg BID for maintenance treatment is not recommended in patients with UC who have known VTE risk factors,&lt;sup&gt;d&lt;/sup&gt; unless there is no suitable alternative treatment available&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/div&gt;&#13;
                &lt;/div&gt;&#13;
                &lt;br/&gt;&lt;br/&gt;&#13;
                &lt;p&gt;&lt;strong style="font-size: 1.1em;color: #ff0148;"&gt;Limitations of overall cohort and OLE data&lt;/strong&gt;&lt;/p&gt;&#13;
                    &lt;p class="bulet"&gt;Pooled, post hoc analysis of studies from the UC clinical trial programme are subject to certain limitations. First, unlike ORAL Surveillance, the patient population is not limited to a high-risk population but includes all enrolled patients. Second, endpoints of interest (such as MACE and malignancy for ORAL Surveillance) were not specifically defined and adjudicated. Additionally, ORAL Surveillance was a long-term safety study (vs shorter term and designed to test efficacy). Resultant incidence rates in ORAL Surveillance differed from rates seen from pooled study data, suggesting the pooled data may be obscuring information about predictors of events given adverse rates may differ from one patient population to another and may change over time&lt;/p&gt;    &#13;
                    &lt;p class="bulet"&gt;OLE studies may provide useful data; however, conduct of OLE studies where both treatment and dose are known to both investigator and patient is subject to certain biases and limitations&lt;/p&gt;    &#13;
                    &lt;p class="bulet"&gt;Biases include, but are not limited to, patient selection (patient willingness or ineligibility to enroll, which may be due to a prior serious AE), prior treatment, volunteer, observer, initial dose or study drug, investigator/patient expectation and study duration. Limitations include, but are not limited to, AE frequencies and incidence rates subject to change over time due to patient entry/exit, dose changes influenced by both investigator and patient, dose restrictions in certain countries, the number of patients and exposure for a specific safety event possibly differing depending on the timing of censored events, and the number of observed patients with longer exposure times becoming lower&lt;/p&gt;    &#13;
                    &lt;p&gt;&lt;strong style="font-size: 1.1em;color: #ff0148;"&gt;Other data sources in UC&lt;/strong&gt;&lt;/p&gt;&#13;
                    &lt;p class="bulet"&gt;It is important to note that the XELJANZ clinical study programme in UC was designed to evaluate the efficacy and safety of XELJANZ in adult patients with moderate to severe UC, and was not specifically designed to assess MACE and malignancy as specific endpoints. Furthermore, the data from the XELJANZ clinical study programme in UC were collected over various time periods (ie, when the studies were conducted as well as study-specific follow-up periods), across varied geographies, and using a variety of analysis methods&lt;/p&gt;    &#13;
                    &lt;p class="bulet"&gt;The XELJANZ clinical study programme in UC was not conducted among a population which was enriched for CV risk, as was the case with&lt;br/&gt; ORAL Surveillance&lt;/p&gt;    &#13;
                    &lt;p class="bulet"&gt;Given these data are from different study populations, have different study designs, and were not designed to assess the specific endpoints of MACE and malignancy, comparative conclusions are inappropriate and, therefore, should not be drawn from this content&lt;/p&gt;&#13;
                    &lt;div class="modal-images"&gt;&#13;
                    &lt;div class="left"&gt;       &#13;
                        &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-3-4.jpg"&gt;&lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                    &lt;div class="right"&gt;       &#13;
                        &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-3-5.png"&gt;&lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                &lt;/div&gt;&#13;
                &lt;div class="small"&gt; &#13;
                    &lt;p&gt;&#13;
                        &lt;sup&gt;a&lt;/sup&gt;XELJANZ offers up to 7.8 years of safety data in UC.&lt;sup&gt;3&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;b&lt;/sup&gt;The rates of the four most frequent AEs occurring in the maintenance trial are listed for the 3 placebo-controlled trials, and the rates of the five most frequently reported&lt;br/&gt; treatment-related AEs are reported for the OLE study.&lt;sup&gt;2,4&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;c&lt;/sup&gt;Duration of treatment varied by patient. Median (max) study drug exposures for XELJANZ 5 mg BID and XELJANZ 10 mg BID were 4.2 (6.6) years and 1.8 (7.0) years, respectively.&lt;sup&gt;2&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;d&lt;/sup&gt;VTE risk factors include previous VTE, patients undergoing major surgery, immobilisation, MI (within previous 3 months), heart failure, use of combined hormonal contraceptives or hormone replacement therapy, inherited coagulation disorder, malignancy. Additional VTE risk factors such as age, obesity (BMI ≥30), diabetes, hypertension, and smoking status should also be considered. Patients should be re-evaluated periodically during XELJANZ treatment to assess for changes in VTE risk.&lt;sup&gt;1&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;e&lt;/sup&gt;Includes data through May 2019 cut-off from OCTAVE Open.&lt;sup&gt;5&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;f&lt;/sup&gt;N=1124.&lt;sup&gt;5&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;g&lt;/sup&gt;Composite MACE defined as any MI, stroke, or CV death.&lt;sup&gt;5&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;h&lt;/sup&gt;Previously reported in Mease, et al. (excludes Study A3921133) and Sandborn, et al.&lt;sup&gt;5&lt;/sup&gt;&#13;
                        &lt;br/&gt;AE, adverse event; BID, twice daily; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; CV, cardiovascular; DVT, deep vein thrombosis; GI, gastrointestinal; &#13;
                        &lt;br/&gt;HZ, herpes zoster; IR, incidence rate (unique patients with events per 100 patient-years); MACE, major adverse cardiovascular event; MI, myocardial infarction; n, number of patients in the disease cohort; n, unique number of patients with event (events are counted up to 28 days beyond the last dose or to the data cut-off date, and are included in the calculation of IR); n1, all events, including those occurring outside the 28-day risk period; NMSC, nonmelanoma skin cancer; OI, opportunistic infection; OLE, open-label extension; PE, pulmonary embolism; PY, patient-year; RA, rheumatoid arthritis; SD, standard deviation; TB, tuberculosis; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis; VTE, venous thromboembolism.&#13;
                    &lt;/p&gt;&#13;
                &lt;/div&gt;&#13;
                &lt;!-----------------------------------------------------------------------------------------&gt;&#13;
                &lt;!-----------------------------------------------------------------------------------------&gt;&#13;
                &lt;div class="title title-bg" style="height: auto;"&gt;&lt;h3 style="line-height: 1.2; font-size: 1.7em;"&gt;&#13;
                ORAL Surveillance: The prespecified noninferiority criterion was not met for the primary comparison of the combined XELJANZ doses with TNFi for adjudicated MACE and malignancies (excluding NMSC)&lt;sup&gt;1&lt;/sup&gt;&lt;/h3&gt;&lt;/div&gt;    &#13;
                &lt;p style="font-size: 1.05em;color: #ff0148;"&gt;&lt;strong&gt;Primary comparisons exceeded the prespecified noninferiority criterion of 1.8. For adjudicated MACE, the HR for the combined XELJANZ doses vs TNFi was 1.33 (95% CI 0.91–1.94). For adjudicated malignancies (excluding NMSC), the HR for the combined XELJANZ doses vs TNFi was 1.48 (95% CI 1.04–2.09).&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#13;
                &lt;div class="modal-images"&gt;&#13;
                    &lt;div class="left" style="width: 44%;"&gt;&#13;
                        &#13;
                        &lt;p class="bulet" style="padding-right: 20px;"&gt;ORAL Surveillance was a randomised, open-label,&#13;
                noninferiority, post-authorisation safety study of&#13;
                XELJANZ in patients with RA who were ≥50 years of&#13;
                age and with ≥1 additional CV risk factor&lt;sup&gt;1,2&lt;/sup&gt;&lt;/p&gt;  &#13;
                        &lt;p class="bulet" style="padding-right: 20px;"&gt;IRs were observed to be higher for XELJANZ compared with TNFi&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;       &#13;
                        &lt;div class="modal-img"&gt;&lt;img src="app/images/q-3-1.jpg"&gt;&lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                    &lt;div class="right" style="width: 56%;&gt;       &#13;
                        &lt;div class="modal-img"&gt;&lt;img src="app/images/q-3-2.jpg"&gt;&lt;/div&gt;&#13;
                    &lt;/div&gt;&#13;
                &lt;/div&gt;&#13;
                &lt;div class="small"&gt; &#13;
                    &lt;p&gt;&#13;
                    &lt;strong&gt;The approved dose of XELJANZ for RA is 5 mg BID.&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt; Pfizer continues to work with the EMA and other regulatory agencies to update XELJANZ labelling in their respective markets based on their ongoing review of the complete ORAL Surveillance results. &#13;
                    &lt;br/&gt;&lt;sup&gt;a&lt;/sup&gt;A 28-day treatment period was used to assess AEs, defined as the minimum of the date of last contact, or the date of the last dose of a trial treatment plus 28 days.&lt;sup&gt;1&lt;/sup&gt;&#13;
                    &lt;br/&gt;&lt;sup&gt;b&lt;/sup&gt;Based on the Cox proportional hazards model.&lt;sup&gt;1&lt;/sup&gt;&#13;
                    &lt;br/&gt;&lt;sup&gt;c&lt;/sup&gt;Also included are opportunistic HZ and tuberculosis events.&lt;sup&gt;1&lt;/sup&gt;&#13;
                    &lt;br/&gt;&lt;sup&gt;d&lt;/sup&gt;Included are HZ adjudicated as an opportunistic infection and nonadjudicated HZ events.&lt;sup&gt;1&lt;/sup&gt;&#13;
                    &lt;br/&gt;AE, adverse event; BID, twice daily; BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; DVT, deep vein thrombosis; EMA, European Medicines Agency; HR, hazard ratio; HZ, herpes zoster; IR, incidence rate; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; OI, opportunistic infection;&lt;br/&gt; PE, pulmonary embolism;   RA, rheumatoid arthritis; SD, standard deviation; TNFi, tumour necrosis factor inhibitor; VTE, venous thromboembolism.&#13;
                    &lt;/p&gt;&#13;
                &lt;/div&gt;</additional3><additional4>&#13;
                &lt;div class="modal-img"&gt;&lt;img src="app/images/additional-4-1.jpg"&gt;&lt;/div&gt;&#13;
                &lt;p class="bulet"&gt;Among patients in remission&lt;sup&gt;a&lt;/sup&gt; on XELJANZ 5 mg BID at week 52 in OCTAVE Sustain, 83% (n=38) maintained remission with XELJANZ 5 mg BID up to 24 months in the OLE study&lt;sup&gt;b&lt;/sup&gt; (observed data)&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;ul&gt;&#13;
                    &lt;li&gt;58% (n=38) maintained remission with XELJANZ 5 mg BID up to 24 months in the OLE study&lt;sup&gt;b&lt;/sup&gt; (NRI-LOCF data)&lt;sup&gt;1&lt;/sup&gt;&lt;/li&gt;        &#13;
                &lt;/ul&gt;&#13;
                &lt;p class="bulet"&gt;Patients in this treatment arm had been in remission&lt;sup&gt;a&lt;/sup&gt; on XELJANZ 5 mg BID at week 52 in OCTAVE Sustain&lt;sup&gt;1&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;p class="bulet"&gt;The recommended dose for maintenance treatment is XELJANZ 5 mg BID. When induction treatment is complete, the dosage should be decreased from 10 mg BID to 5 mg BID&lt;sup&gt;2&lt;/sup&gt;&lt;/p&gt;&#13;
                &lt;div class="small"&gt;&#13;
                    &lt;p&gt;&#13;
                        &lt;sup&gt;a&lt;/sup&gt;Remission was defined as a total Mayo score ≤2 with no individual subscore &gt;1 and a rectal bleeding subscore of 0.&lt;sup&gt;1&lt;/sup&gt;&#13;
                        &lt;br/&gt;&lt;sup&gt;b&lt;/sup&gt;Limitations: this is a post hoc analysis of data from an OLE study of XELJANZ in a subpopulation of patients with moderate-to-severe UC meeting remission criteria following completion of the 52-week OCTAVE Sustain study.&lt;sup&gt;1&lt;/sup&gt; OLE studies have inherent biases. For this analysis from the OLE study, treatment and dose were known to investigator and patient, there was no comparator arm, and the sample size was small.&lt;sup&gt;1&lt;/sup&gt; This analysis should be interpreted with caution while taking these considerations into account.&#13;
                        &lt;br/&gt;BID, twice daily; n, number of patients in the maintenance remission subpopulation with the specified response within the given category; N, number of patients in the maintenance remission subpopulation with non-missing values who could have reached the specified timepoint (based on enrollment date and last non-missing total Mayo score);&lt;br/&gt;  NRI-LOCF, non-responder imputation-last observation carried forward; OLE, open-label extension; UC, ulcerative colitis.     &#13;
                    &lt;/p&gt;&#13;
                &lt;/div&gt;  </additional4><aditionalList><aditional1><id>0</id><title>Additional Information</title></aditional1><additional2><id>1</id><title>Additional Information</title></additional2><aditional3><id>2</id><title>XELJANZ SAFETY PROFILE IN UC</title></aditional3><aditional4><id>3</id><title>Additional Information</title></aditional4></aditionalList></additional-info></item></pages></document>
